The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 7, 2001, Pages 571-588

  Mair, J ^a   Hammerer Lercher, A ^a   Puschendorf, B ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Heart failure; N terminal pro atrial natriuretic peptide; N terminal pro brain natriuretic peptide; Risk stratification; Ventricular dysfunction

Indexed keywords

ANTIMITOTIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR; NATRIURETIC FACTOR; NEUROHORMONE; VASODILATOR AGENT;

AMINO TERMINAL SEQUENCE; ASCITES; BLOOD VOLUME; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DIURESIS; EDEMA; ENDOCRINE FUNCTION; FOLLOW UP; HEART ATRIUM PRESSURE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE; HEART VOLUME; HEART WORK; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; NATRIURESIS; PEPTIDE SYNTHESIS; PHYSICIAN; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT;

ATRIAL NATRIURETIC FACTOR; CHEMISTRY, CLINICAL; DIMERIZATION; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, BIOLOGICAL; NATRIURETIC PEPTIDE, BRAIN; REFERENCE VALUES; RISK FACTORS;

EID: 0034911020     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.093     Document Type: Review

References (116)

1. Myocardial infarction redefined - A consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction
2. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats
3. Atrial natriuretic peptide elevation in congestive heart failure in human
4. The epidemiology of heart failure
5. Epidemiology of heart failure and left ventricular dysfunction
6. Incidence and aetiology of heart failure
7. Prevalence of heart failure and left ventricular dysfunction in the general population - The Rotterdam Study
8. Symptomatic and asymptomatic left-ventricular dysfunction in an urban population
9. Consensus Recommendations for the management of chronic heart failure
10. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure
11. The natural history of congestive heart failure: The Framingham study
12. The neurohumoral hypothesis: A theory to explain the mechanism of disease progression in heart failure
13. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP)
14. A new natriuretic peptide in porcine brain
15. C-type natriuretic peptide (CNP): A new member of the natriuretic peptide family identified in porcine brain
16. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
17. Contrasting cardiac regional responses of A-type and B-type natriuretic peptide to experimental chronic heart failure
18. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
19. Regulation of natriuretic peptide secretion by the heart
20. Regulation of gene expression in the endocrine heart
21. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression
22. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis
23. Developmental stage-specific regulation of atrial natriuretic factor gene transcription in cardiac cells
24. Characterization of natriuretic peptide production by adult heart atria
25. Molecular biology of the natriuretic peptides and their receptors
26. Natriuretic Peptides
27. The natriuretic-peptide family
28. Circulating beta-atrial natriuretic factor in congestive heart failure in humans
29. Localization of the mosaic transmembrane serine protease corin to heart myocytes
30. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme
31. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes
32. Effect of atrial natriuretic peptide on thirst and arginine vasopressin release in humans
33. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide
34. Cardiac fibrosis in mice lacking brain natriuretic peptide
35. Hormones and hemodynamics in heart failure
36. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption
37. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
38. Structure of the dimerized hormone-binding domain of a guanylyl-cyclase-coupled receptor
39. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system
40. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure
41. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure
42. Vasopeptidase inhibition: A new concept in blood pressure management
43. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts
44. Cardiac peptide stability, aprotinin and room temperature: Importance for assessing cardiac function in clinical practice
45. Plasma atrial natriuretic peptide is unstable under most storage conditions
46. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: An important prerequisite for its use as a biochemical marker of atrial pressure in clinical routine
47. Measurement of brain natriuretic peptide
48. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma
49. Immunoreactive amino-terminal probrain natriuretic peptide (NT-proBNP): A new marker of cardiac impairment
50. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: Implications for assessment of left ventricular dysfunction
51. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit
52. A new fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases
53. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans
54. 24-h variation in atrial natriuretic peptide
55. Variable patterns of atrial natriuretic peptide secretion in man
56. Is the secretion of atrial natriuretic peptide under neural control?
57. Atrial natriuretic peptide: Synthesis, release, and metabolism
58. Release of atrial natriuretic peptide during pregnancy and immediate puerperium
59. Circulating levels of cardiac natriuretic hormones measured in women during menstrual cycle
60. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure
61. Analytical performance and clinical usefulness of a commercially available IRMA kit for measuring atrial natriuretic peptide in patients with heart failure
62. B-type natriuretic peptide (BNP) - Validation of an immediate response assay
63. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: Investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide natriuretic peptide (1-30) and atrial natriuretic peptide (99-126)
64. Enzyme immunoassay for fragments (epitopes) of human proatrial natriuretic peptides
65. Immunoradiometric assay for N-terminal fragment of proatrial natriuretic peptide (N-terminal proANP) in human plasma
66. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: The need for a new generation of immunoassay methods
67. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?
68. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescendence: Marked and rapid increase after birth
69. Relationship between natriuretic peptides and hemodynamics in patients with heart failure at rest and after ergometric exercise
70. Natriuretic peptides and cyclic guanosine 3′,5′-monophosphate in asymptomatic and symptomatic left ventricular dysfunction
71. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
72. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
73. Biochemical detection of left-ventricular dysfunction
74. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
75. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction
76. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy
77. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study
78. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program
79. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): A new marker of cardiac impairment
80. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population
81. Profile of plasma N-terminal proBNP following acute myocardial infarction - Correlation with left ventricular dysfunction
82. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
83. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril
84. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction
85. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure - Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic dysfunction
86. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction - Comparison with angiotensin II and endothelin-1
87. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure
88. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomised comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy
89. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
90. Neurohormonal prediction of benefit from carvedilol in ischemic left ventricular dysfunction
91. Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension
92. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension
93. Expression of brain natriuretic peptide gene in human heart: Production in the ventricle
94. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease
95. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension
96. Augmented release of brain natriuretic peptide during reperfusion of the human heart after cardioplegic cardiac arrest
97. Plasma levels of atrial natriuretic peptide during myocardial ischemia induced by percutaneous transluminal coronary angioplasty or dynamic exercise
98. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
99. Early decrease of atrial natriuretic peptide in acute myocardial infarction
100. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction
101. Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction
102. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction
103. N-terminal proatrial natriuretic factor - An independent predictor of long-term prognosis after myocardial infarction
104. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction - Comparison with plasma atrial natriuretic peptide and natriuretic peptide
105. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension
106. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension
107. Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure
108. Neurohumoral responses to a single haemodialysis in chronic renal failure patients
109. N-terminal fragments of proatrial natriuretic peptide in patients before and after hemodialysis treatment
110. Plasma human brain natriuretic peptide in chronic renal failure
111. Diagnostic potential of cardiac natriuretic peptides in dialysis patients
112. Prolonged stability of brain natriuretic peptide: Importance for non-invasive assessment of cardiac function in clinical practice
113. Stabilization of human brain natriuretic peptide in blood
114. Stability of human plasma atrial natriuretic peptide during storage at -80 °C
115. Enzymimunoassays für proBNP Fragmente (8-29) und (32-57)
116. Comparison of N-terminal pro-atrial natriuretic peptide and atrial natriuretic peptide in human plasma as measured with commercially available radioimmunoassay kits